Navigation Links
Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
Date:7/6/2010

DANBURY, Conn., July 6 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U.S.A. next week.

Oral Presentation:

#51, Oral session on peptides and proteins, Monday July 12, 2010 4:00 PM (PT) "'Smart' Basal Insulin Formulation that Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine," to be presented by N. Kashyap, Biodel Inc.

Poster Presentation:

#373, Poster session on peptides and proteins, Monday July 12, 2010 1:00 PM - 2:00 PM (PT) "Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine," to be presented by Dr. R. Pohl, Biodel Inc.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
2. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
3. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
4. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
6. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
7. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
8. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
9. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
10. Sysmex America Announces Executive Leadership Changes
11. FUISZ Announces Advances in Devices and Solid Dosage Form
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)... May 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... which enables the functional selection of stem cells, today ... the first quarter ended March 31 st , 2017. ... accomplishments in the first quarter of 2017," said Dr. ... we announced the treatment of the first blood cancer ...
(Date:5/22/2017)... 22, 2017  Lilac Corp, the company that ... launch of a new website . The ... a clinical study that showed surprising clearance of ... in individuals suffering from HPV warts, precancerous, or ... are no other treatments that clear the virus. ...
Breaking Medicine Technology:
(Date:6/27/2017)... Valley, CA (PRWEB) , ... June 27, 2017 , ... ... since 2001 suffer from PTSD. Yet less than 20% will receive adequate care due ... those with PTSD won't receive any care at all. And left untreated, veterans are ...
(Date:6/26/2017)... Torrance, CA (PRWEB) , ... June 26, 2017 , ... ... treatments. Smile aesthetics can be one of the most noticeable aspects of a person’s ... approachable. While not everyone is born with beautiful, balanced teeth, everyone can have the ...
(Date:6/26/2017)... ... 26, 2017 , ... Maryland’s soybean farmers have improved the ... by the United Soybean Board. , Thanks to the responsible use of ... productivity on less land per bushel, the report says. The United Soybean Board’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a protocol built on ... to solve many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, ... crowdfunding - the raising of funds through the power of many - has been ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version ... It differs significantly from the American Health Care Act, which the House passed in ... House will have to take up the Senate version as-is, if it passes. , ...
Breaking Medicine News(10 mins):